The present application discloses 17ß hydroxy steroid dehydrogenase (17ß HSD) type 1, 3, 10 inhibitors and use thereof (alone and in combination) in the treatment of cancer and other afflictions. 17ß HSDl inhibitors include estradiol derivatives with a nieta-carbamoylbenzyl substituent at C 16. 17ß HSD3/HSD10 inhibitors include androsterone derivatives substituted at the C3 position with a sulfonamide piperazine. Also disclosed are compounds that are inhibitors of both 17ß HSDl and 17ß HSD3 that have a spiro-morpholine substituent at C20.